AstraZeneca

INSURERS LEFT IN THE BANKS’ DUST

28/01/26 -"It took a Trumpian ‘liberation’ day to decouple European insurers from European banks. While the Banks to Insurance ratio remained between 1x and 1.2x over most of the last 5 years, suddenly things ..."

PDF page sample
Pages
63
Language
English
Published on
28/01/26
Download
You may also be interested by these reports :
29/01/26
The 2025 performance delivered on the management’s guidance, backed by a strong showing from the cornerstone immunology medicine Dupixent, newly ...
29/01/26
Roche finished the year on a strong note, backed by healthy performances across key focus areas. Even the 2026 guidance was encouraging. The ...
28/01/26
Lonza’s full-year 2025 CDMO performance surpassed management’s guidance. Top-line growth was driven by strong double-digit increases in Integrated ...
28/01/26
2025 was a year of US tariff threats and drug pricing pressure on the pharma industry, and for AstraZeneca (REDUCE; UK), it started under the cloud ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO